GlassScriptPhysician profile
Thomas P Mathew
NPI 1841339090
$1,308.90
in general payments reported to CMS, 2019-2025
12 companies · $96.27 in 2025
The $96.27 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.22 · 2020: $104 · 2021: $393 · 2022: $292 · 2023: $274 · 2024: $96.07 · 2025: $96.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $465.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $626.27 | 2019-2025 | |
| Celgene Corporation | $126.25 | 2021-2024 | Zeposia |
| Acelrx Pharmaceuticals, INC. | $116.56 | 2021 | |
| Janssen Biotech, INC. | $113.33 | 2023 | Stelara |
| Boston Scientific Corporation | $96.97 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.07 | 2020 | |
| Pfizer INC. | $43.44 | 2022 | |
| Nestle Healthcare Nutrition INC. | $29.31 | 2021-2022 | |
| Lilly USA, LLC | $24.13 | 2023 | |
| Intercept Pharmaceuticals, INC. | $17.59 | 2025 | |
| Medtronic, INC. | $15.09 | 2023 | Gi Genius |
| Allergan, INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.